Share：
Share this content in WeChat
X
[Chinese][PDF]4239
• Special Focus •
Application value of IDEAL-IQ sequence in differential diagnosis of benign and malignant breast masses
YU Jiaping  DU Siyao  HAN Rui  ZHAO Ruimeng  ZHANG Lina 

Cite this article as: YU J P, DU S Y, HAN R, et al. Application value of IDEAL-IQ sequence in differential diagnosis of benign and malignant breast masses[J]. Chin J Magn Reson Imaging, 2024, 15(1): 14-20, 42. DOI:10.12015/issn.1674-8034.2024.01.003.


[Abstract] Objective To investigate the diagnostic significance of R2* values obtained from iterative decomposition of water and fat with echo asymmetrical and least-squares estimation quantitation sequence (IDEAL-IQ) in distinguishing between benign and malignant breast tumors, and compare these values with those obtained from traditional multiple echo T2* gradient recalled echo (GRE) series.Materials and Methods A total of 50 cases of benign tumors in 42 patients admitted to the First Hospital of China Medical University from September 2021 to October 2023 were retrospectively analyzed. The propensity score matching was used to match the longest diameter of the largest plane of the tumor in picture archiving and communication systems (PACS), and 150 cases of malignant tumors in 150 patients were included according to the 1∶3 ratio. Malignant tumors were grouped based on the positive/negative expression of prognostic factors such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). All patients underwent multi-parameter MRI with IDEAL-IQ and multi-echo T2* GRE sequences, and the following quantitative parameters were measured: R2* IDEAL from IDEAL-IQ sequence, R2* GRE from multi-echo T2* GRE sequence, apparent diffusion coefficient (ADC), and tumor diameter. The intra-class correlation coefficient (ICC) was used to evaluate the consistency between the researchers. Depending on the type of raw data, the differences of each parameter were compared and analyzed using one-way analysis (independent samples t-test, Mann-Whitney U-test, etc.). Spearman correlation analysis was used to analyze the correlation between R2* IDEAL and R2* GRE, as well as their correlation with ADC. The difference between R2* IDEAL and R2* GRE was compared by paired sample t-test. A joint diagnostic model was established by using logistic regression analysis, and the receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to analyze the efficacy of single and combined parameters in differentiating benign and malignant breast tumors.Results Correlation analysis showed that R2* IDEAL and R2* GRE in patients with breast tumors were moderately strongly correlated (r=0.763, P<0.001), and both were weakly negatively correlated with ADC values [r=-0.300 (R2* IDEAL), -0.306 (R2* GRE), P<0.001]. In benign group and malignant group, R2* IDEAL and R2* GRE showed moderate correlation (r=0.745, 0.680, P<0.001), and there was no correlation between them and ADC. The R2* values obtained by the two sequences were statistically different (P<0.05). There was a significant difference in R2* IDEAL between benign and malignant groups (P<0.001), and the R2* value of luminal HER-2 negative group was the highest. For a single parameter, ADC value had the largest AUC (0.857) in differentiating benign and malignant groups. For the combined parameters, R2* IDEAL+ADC had the largest AUC (0.927) in differentiating benign group from luminal negative group. The differences were statistically significant (P<0.05).Conclusions The R2* value generated by IDEAL-IQ sequence can be used to distinguish benign and malignant breast tumors, and may be another non-contrast parameter in addition to ADC to assist the differentiation of benign and malignant breast tumors.
[Keywords] breast neoplasms；distinguish between benign and malignant；molecular subtype；iterative decomposition of water and fat with echo asymmetrical and least-squares estimation quantitation sequence；diffusion weighted imaging；magnetic resonance imaging

YU Jiaping1   DU Siyao1   HAN Rui2   ZHAO Ruimeng1   ZHANG Lina1*  

1 Department of Radiology, the First Hospital of China Medical University, Shenyang 110001, China

2 The First Clinical College, China Medical University, Shenyang 110001, China

Corresponding author: ZHANG L N, E-mail: zhanglnda@163.com

Conflicts of interest   None.

Received  2023-08-30
Accepted  2023-12-29
DOI: 10.12015/issn.1674-8034.2024.01.003
Cite this article as: YU J P, DU S Y, HAN R, et al. Application value of IDEAL-IQ sequence in differential diagnosis of benign and malignant breast masses[J]. Chin J Magn Reson Imaging, 2024, 15(1): 14-20, 42. DOI:10.12015/issn.1674-8034.2024.01.003.

[1]
SIEGEL R, MILLER K, WAGLE N S, et al. Cancer statistics, 2023[J/OL]. CA A Cancer J Clin, 2023, 73: 17-48 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/36633525/. DOI: 10.3322/caac.21763.
[2]
BALIU-PIQUÉ M, PANDIELLA A, OCANA A. Breast cancer heterogeneity and response to novel therapeutics[J/OL]. Cancers, 2020, 12(11): 3271 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/33167363/. DOI: 10.3390/cancers12113271.
[3]
CORTAZAR P, ZHANG L J, UNTCH M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172. DOI: 10.1016/S0140-6736(13)62422-8.
[4]
LEITHNER D, HORVAT J V, MARINO M A, et al. Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results[J/OL]. Breast Cancer Res, 2019, 21(1): 106 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/31514736/. DOI: 10.1186/s13058-019-1187-z.
[5]
JEONG Y S, KANG J, LEE J, et al. Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer[J]. J Pathol Transl Med, 2020, 54(1): 87-94. DOI: 10.4132/jptm.2019.10.14.
[6]
CONTI A, DUGGENTO A, INDOVINA I, et al. Radiomics in breast cancer classification and prediction[J/OL]. Semin Cancer Biol, 2021, 72: 238-250 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/32371013/. DOI: 10.1016/j.semcancer.2020.04.002.
[7]
XIAO J, RAHBAR H, HIPPE D S, et al. Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis[J/OL]. NPJ Breast Cancer, 2021, 7(1): 42 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/33863924/. DOI: 10.1038/s41523-021-00247-3.
[8]
SAD L M A E A, DABEES N L, MOHAMED D A E, et al. Assessment of suspected breast lesions in early-stage triple-negative breast cancer during follow-up after breast-conserving surgery using multiparametric MRI[J/OL]. Int J Breast Cancer, 2022, 2022: 4299920 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/35223102/. DOI: 10.1155/2022/4299920.
[9]
BLOMQVIST L, NORDBERG G F, NURCHI V M, et al. Gadolinium in medical imaging-usefulness, toxic reactions and possible countermeasures-a review[J/OL]. Biomolecules, 2022, 12(6): 742 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/35740867/. DOI: 10.3390/biom12060742.
[10]
WEINREB J C, RODBY R A, YEE J, et al. Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American college of radiology and the national kidney foundation[J]. Radiology, 2021, 298(1): 28-35. DOI: 10.1148/radiol.2020202903.
[11]
AHN Y H, KANG D Y, PARK S B, et al. Allergic-like hypersensitivity reactions to gadolinium-based contrast agents: an 8-year cohort study of 154 539 patients[J]. Radiology, 2022, 303(2): 329-336. DOI: 10.1148/radiol.210545.
[12]
LIU X, ZHANG Y F, CUI X, et al. Gadopentetate meglumine activates mast cells to cause IgE-independent allergic reactions both in vitro and in vivo[J/OL]. Int Immunopharmacol, 2022, 106: 108602 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/35131571/. DOI: 10.1016/j.intimp.2022.108602.
[13]
HORVAT J V, BERNARD-DAVILA B, HELBICH T H, et al. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer[J]. J Magn Reson Imaging, 2019, 50(3): 836-846. DOI: 10.1002/jmri.26697.
[14]
PARTRIDGE S C, NISSAN N, RAHBAR H, et al. Diffusion-weighted breast MRI: clinical applications and emerging techniques[J]. J Magn Reson Imaging, 2017, 45(2): 337-355. DOI: 10.1002/jmri.25479.
[15]
MENG L S, ZHAO X, GUO J X, et al. Improved differential diagnosis based on BI-RADS descriptors and apparent diffusion coefficient for breast lesions: a multiparametric MRI analysis as compared to Kaiser score[J]. Acad Radiol, 2023, 30(Suppl 2): S93-S103. DOI: 10.1016/j.acra.2023.03.035.
[16]
CHEN X, HE X J, JIN R, et al. Conspicuity of breast lesions at different b values on diffusion-weighted imaging[J/OL]. BMC Cancer, 2012, 12: 334 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/22853049/. DOI: 10.1186/1471-2407-12-334.
[17]
LIN C X, TIAN Y, LI J M, et al. Diagnostic value of multiple b-value diffusion-weighted imaging in discriminating the malignant from benign breast lesions[J/OL]. BMC Med Imaging, 2023, 23(1): 10 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/36631781/. DOI: 10.1186/s12880-022-00950-y.
[18]
ZHAO M, FU K, ZHANG L, et al. Intravoxel incoherent motion magnetic resonance imaging for breast cancer: a comparison with benign lesions and evaluation of heterogeneity in different tumor regions with prognostic factors and molecular classification[J]. Oncol Lett, 2018, 16(4): 5100-5112. DOI: 10.3892/ol.2018.9312.
[19]
DORRIUS M D, DIJKSTRA H, OUDKERK M, et al. Effect of b value and pre-admission of contrast on diagnostic accuracy of 1.5-T breast DWI: a systematic review and meta-analysis[J]. Eur Radiol, 2014, 24(11): 2835-2847. DOI: 10.1007/s00330-014-3338-z.
[20]
OTIKOVS M, NISSAN N, FURMAN-HARAN E, et al. Diffusivity in breast malignancies analyzed for b > 1000 s/mm2 at 1 mm in-plane resolutions: insight from Gaussian and non-Gaussian behaviors[J]. J Magn Reson Imaging, 2021, 53(6): 1913-1925. DOI: 10.1002/jmri.27489.
[21]
JEON K J, LEE C N, CHOI Y J, et al. Assessment of bone marrow fat fractions in the mandibular condyle head using the iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL-IQ) method[J/OL]. PLoS One, 2021, 16(2): e0246596 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/33635882/. DOI: 10.1371/journal.pone.0246596.
[22]
PENG Y, ZOU X L, CHEN G, et al. Chemical shift-encoded sequence (IDEAL-IQ) and amide proton transfer (APT) MRI for prediction of histopathological factors of rectal cancer[J/OL]. Bioengineering, 2023, 10(6): 720 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/37370651/. DOI: 10.3390/bioengineering10060720.
[23]
ZHANG L J, ZHANG Z L, XU J, et al. Carbogen gas-challenge blood oxygen level-dependent magnetic resonance imaging in hepatocellular carcinoma: initial results[J]. Oncol Lett, 2015, 10(4): 2009-2014. DOI: 10.3892/ol.2015.3526.
[24]
SHI G Z, CHEN H, ZENG W K, et al. R2* value derived from multi-echo Dixon technique can aid discrimination between benign and malignant focal liver lesions[J]. World J Gastroenterol, 2021, 27(12): 1182-1193. DOI: 10.3748/wjg.v27.i12.1182.
[25]
KIM Y, PARK J J, KIM C K. Blood oxygenation level-dependent MRI at 3T for differentiating prostate cancer from benign tissue: a preliminary experience[J/OL]. Br J Radiol, 2022, 95(1131): 20210461 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/34235962/. DOI: 10.1259/bjr.20210461.
[26]
ZHU P P, HE F, HOU Y X, et al. A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability[J]. Oncogene, 2021, 40(9): 1609-1627. DOI: 10.1038/s41388-020-01638-9.
[27]
LIU M, GUO X J, WANG S K, et al. BOLD-MRI of breast invasive ductal carcinoma: correlation of R2* value and the expression of HIF-1α[J]. Eur Radiol, 2013, 23(12): 3221-3227. DOI: 10.1007/s00330-013-2937-4.
[28]
MCPHAIL L D, ROBINSON S P. Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis[J]. Radiology, 2010, 254(1): 110-118. DOI: 10.1148/radiol.2541090395.
[29]
HAMMOND M E, HAYES D F, DOWSETT M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784-2795. DOI: 10.1200/JCO.2009.25.6529.
[30]
WOLFF A C, HAMMOND M E, HICKS D G, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31): 3997-4013. DOI: 10.1200/JCO.2013.50.9984.
[31]
GE M M, ZHANG J, WU B, et al. Effect of gadolinium on hepatic fat quantification using multi-echo reconstruction technique with T2* correction and estimation[J]. Eur Radiol, 2016, 26(6): 1913-1920. DOI: 10.1007/s00330-015-3981-z.
[32]
AOKI T, YAMAGUCHI S, KINOSHITA S, et al. Quantification of bone marrow fat content using iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): reproducibility, site variation and correlation with age and menopause[J/OL]. Br J Radiol, 2016, 89(1065): 20150538 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/27356277/. DOI: 10.1259/bjr.20150538.
[33]
HISANAGA S, AOKI T, SHIMAJIRI S, et al. Peritumoral fat content correlates with histological prognostic factors in breast carcinoma: a study using iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL)[J]. Magn Reson Med Sci, 2021, 20(1): 28-33. DOI: 10.2463/mrms.mp.2019-0201.
[34]
WU L M, CHEN X X, XUAN H Q, et al. Feasibility and preliminary experience of quantitative T2* mapping at 3.0 T for detection and assessment of aggressiveness of prostate cancer[J]. Acad Radiol, 2014, 21(8): 1020-1026. DOI: 10.1016/j.acra.2014.04.007.
[35]
WANG H, JIANG H, VAN DE GUCHT M, et al. Hypoxic radioresistance: can ROS be the key to overcome it?[J/OL]. Cancers, 2019, 11(1): 112 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/30669417/. DOI: 10.3390/cancers11010112.
[36]
SRIVASTAVA N, USMANI S S, SUBBARAYAN R, et al. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens[J/OL]. Front Oncol, 2023, 13: 1199105 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/37492478/. DOI: 10.3389/fonc.2023.1199105.
[37]
CHAVHAN G B, BABYN P S, THOMAS B, et al. Principles, techniques, and applications of T2*-based MR imaging and its special applications[J]. Radiographics, 2009, 29(5): 1433-1449. DOI: 10.1148/rg.295095034.
[38]
MIYATA M, AOKI T, SHIMAJIRI S, et al. Evaluation of the R2* value in invasive ductal carcinoma with respect to hypoxic-related prognostic factors using iterative decomposition of water and fat with echo asymmetry and least-squares emission (IDEAL)[J]. Eur Radiol, 2017, 27(10): 4316-4323. DOI: 10.1007/s00330-017-4832-x.
[39]
JIANG L, WEATHERALL P T, MCCOLL R W, et al. Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study[J]. J Magn Reson Imaging, 2013, 37(5): 1083-1092. DOI: 10.1002/jmri.23891.
[40]
BENNANI-BAITI B, PINKER K, ZIMMERMANN M, et al. Non-invasive assessment of hypoxia and neovascularization with MRI for identification of aggressive breast cancer[J/OL]. Cancers, 2020, 12(8): 2024 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/32721996/. DOI: 10.3390/cancers12082024.
[41]
WANG Y C, SHEN Y Q, HU X M, et al. Application of R2* and apparent diffusion coefficient in estimating tumor grade and T category of bladder cancer[J]. AJR Am J Roentgenol, 2020, 214(2): 383-389. DOI: 10.2214/AJR.19.21668.
[42]
SYED A K, WHISENANT J G, BARNES S L, et al. Multiparametric Analysis of Longitudinal Quantitative MRI data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer[J/OL]. Cancers, 2020, 12(6): 1682 [2023-08-29]. https://pubmed.ncbi.nlm.nih.gov/32599906/. DOI: 10.3390/cancers12061682.
[43]
BALTZER P, MANN R M, IIMA M, et al. Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group[J]. Eur Radiol, 2020, 30(3): 1436-1450. DOI: 10.1007/s00330-019-06510-3.
[44]
HAAK H E, MAAS M, LAHAYE M J, et al. Selection of patients for organ preservation after chemoradiotherapy: MRI identifies poor responders who can go straight to surgery[J]. Ann Surg Oncol, 2020, 27(8): 2732-2739. DOI: 10.1245/s10434-020-08334-8.

PREV Diagnostic value of MRI features combined with clinicopathologic features in predicting the expression of human epidermal growth factor receptor 2 in breast cancer
NEXT Different MRI features between BRCA mutant and non-mutant breast cancer patients
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn